Send to printer »

GEN News Highlights : Nov 10, 2009

Sigma-Aldrich to Distribute Stemgent’s Gene Delivery Products for iPS Cells

Sigma-Aldrich entered into an exclusive, worldwide distribution agreement to offer Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells. The reprogramming technologies offered under the terms of the agreement involve viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich, and dox Inducible expression from TET Systems.

“Induced pluripotent stem cells have emerged as immensely useful tools for the modeling of human diseases, research and development of therapeutics, regenerative medicine, and the development of personalized cell-replacement therapies,” comments David Smoller, Ph.D., president of Sigma-Aldrich's research biotech business unit.